AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Hoodline

Published November 14, 2026 · Updated November 15, 2026

U.S. funds ibogaine PTSD trial prep, not treatment - Hoodline

Read the full story at Hoodline

Kennedy said ARPA-H will spend up to $4.9 million preparing ibogaine trials for veterans with PTSD. The awards do not fund patient treatment.

Post on X

Share this story

Surfaced by this Google Alert

Ibogaine